What is AxisPharm?
AxisPharm operates as a global contract research organization (CRO) with a specialized focus on bioconjugation and the production of ADC linkers. The company offers a comprehensive suite of services, encompassing analytical support, proteomics, metabolomics, and custom synthesis, all meticulously tailored to meet the demanding requirements of biotech and pharmaceutical firms. With an extensive catalog of over 5,000 high-purity reagents, AxisPharm is instrumental in advancing research and development in drug delivery and bioconjugation technologies. Its reputation for quality and competitive pricing has established it as a valued partner within the life sciences ecosystem.
How much funding has AxisPharm raised?
AxisPharm has raised a total of $49K across 1 funding round:
Debt
$49K
Debt (2021): $49K with participation from PPP
What's next for AxisPharm?
The significant Series B/C stage funding positions AxisPharm for accelerated growth and enhanced market penetration. This capital infusion is expected to drive strategic initiatives, potentially including the expansion of manufacturing capabilities, further investment in research and development for novel bioconjugation techniques, and the broadening of its service portfolio. AxisPharm is poised to capitalize on the increasing demand for specialized CRO services, particularly in the rapidly evolving field of targeted therapeutics like ADCs. The company's trajectory suggests a focus on solidifying its leadership in bioconjugation and ADC linker manufacturing, thereby supporting the development of next-generation pharmaceuticals.
See full AxisPharm company page
